Methylphenidate Immediate-Release 30mg Formulation
No immediate-release (IR) methylphenidate product is commercially available in a 30 mg strength. 1
Available IR Methylphenidate Strengths
According to FDA labeling, methylphenidate hydrochloride oral solution (the IR formulation) is only available in two strengths:
- 5 mg per 5 mL
- 10 mg per 5 mL 1
The FDA prescribing information for IR methylphenidate oral solution specifies that the recommended starting dosage for pediatric patients 6 years and older is 5 mg orally twice daily, with gradual increases in increments of 5 mg to 10 mg weekly. The maximum recommended daily dose is 60 mg 1. However, this is achieved through multiple doses of the available strengths, not through a single 30 mg tablet or formulation.
Clinical Context
The guideline literature discusses IR methylphenidate primarily in comparison to extended-release formulations, noting that IR formulations typically require multiple daily doses (bid or tid dosing) 2. The evidence indicates that IR methylphenidate produces higher peak plasma concentrations with a steeper absorption profile compared to sustained-release preparations, with onset of action at approximately 30 minutes and peak benefit occurring around 2 hours post-dose 2.
Important Caveat
If you are seeking a 30 mg dose of methylphenidate, this would need to be achieved by:
- Administering 30 mL of the 5 mg/5 mL oral solution (providing 30 mg total)
- Administering 15 mL of the 10 mg/5 mL oral solution (providing 30 mg total)
- Using multiple lower-strength IR tablets if tablet formulations are available (though specific tablet strengths were not detailed in the provided FDA labeling)
There is no single-unit 30 mg IR methylphenidate product marketed in the United States.